Impact of decreased renal function on coagulation and fibrinolysis in patients with non-valvular atrial fibrillation

Circulation Journal

Volumn 73, Issue 5, 2009, Pages 846-850

  Tanaka, Hideki ^a   Sonoda, Masahiro ^a   Kashima, Katsuro ^a   Tanaka, Yasuhiro ^a   Nakamura, Kazuhiko ^a   Nuruki, Norihito ^b   Tsubouchi, Hirohito ^b  

^a NATIONAL HOSPITAL ORGANIZATION KAGOSHIMA MEDICAL CENTER   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Coagulation; Non valvular atrial fibrillation; Renal function; Risk factor of thromboembolic event

Indexed keywords

ACETYLSALICYLIC ACID; D DIMER; THROMBIN ANTITHROMBIN COMPLEX; TICLOPIDINE;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEMOSTASIS; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANTITHROMBIN III; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; BLOOD COAGULATION; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY DISEASES; LINEAR MODELS; MALE; MIDDLE AGED; PEPTIDE HYDROLASES; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS;

EID: 65649087097     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-08-0484     Document Type: Article

References (33)

1. Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The Framingham Study. Neurology 1978; 28: 973-977. (Pubitemid 8401525)
2. Tanaka H, Hayashi M, Date C, Iwai K, Asada M, Shoji H, et al. Epidemiologic studies of stroke in Shibata, a Japanese provincial city: Preliminary report on risk factors for cerebral infarction. Stroke 1985; 16: 773-780. (Pubitemid 15246745)
3. Flegel KM, Shipley MJ, Rose G. Risk of stroke in nonrheumatic atrial fibrillation. Lancet 1987; 1: 526-529. (Pubitemid 17020736)
4. Ohsawa M, Okayama A, Okamura T, Itai K, Nakamura M, Tanno K, et al. Mortality risk attributable to atrial fibrillation in middle-aged and elderly people in the Japanese general population: Nineteen year follow-up in NIPPON DATA80. Circ J 2007; 71: 814-819. (Pubitemid 46833916)
5. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation I: Clinical features of patients at risk. Ann Intern Med 1992; 116: 1-5.
6. Moulton AW, Singer DE, Haas JS. Risk factors for stroke in patients with non-rheumatic atrial fibrillation: A case-control study. Am J Med 1991; 91: 156-161.
7. Hiroshi I, Takashi N, Tadakazu H, Atsushi I, Ken O, Jong-Dae Lee. Accumulation of risk factors increases risk of thromboembolic events in patients with nonvalvular atrial fibrillation. Circ J 2006; 70: 651-656. (Pubitemid 43803693)
8. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation II: Echocardiographic features of patients at risk. Am Intern Med 1992; 116: 6-12.
9. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697-702.
10. Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988; 59: 101-106. (Pubitemid 18053658)
11. Rylatt DB, Blake AS, Cottis LE, Massingham DA, Fletcher WA, Masci PP, et al. An immunoassay for human D-dimer using monoclonal antibodies. Thomb Res 1983; 31: 767-778. (Pubitemid 14227169)
12. Elms MJ, Bunce IH, Bundesen PG, Rylatt DB, Webber AJ, Masci PP, et al. Rapid detection of cross-linked fibrin degradation products in plasma using monoclonal antibody-coated latex particles. Am J Clin Pathol 1986; 85: 360-364. (Pubitemid 16071226)
13. Tomura S, Nakamura Y, Deguchi F, Chida Y, Ohno Y, Kodama S, et al. Plasma Von Willebrand factor and thrombomodulin as markers of vascular disorders in patients undergoing regular hemodialysis therapy. Thromb Res 1990; 58: 413-419. (Pubitemid 20146933)
14. Knudsen F, Dyerberg J. Platelets and antithrombin III in uremia: The acute effect of haemodialysis. Scand J Clin Lab Invest 1985; 45: 341-347. (Pubitemid 15049476)
15. Levin R, Hau CK, Ivanovic P. Changes in platelet function during hemodialysis. J Lab Clin Med 1978; 92: 779-786. (Pubitemid 9058666)
16. Green D, Santhanam S, Krumlovsky FA, Del Greco F. Elevated β-thromboglobulin in patients with chronic renal failure: Effect of hemodialysis. J Lab Clin Med 1980; 95: 679-685. (Pubitemid 10098117)
17. Krutz H, Lerner RG, Weseley S, Nelson JC. Changes in fibrinolytic activity during the course of a single hemodialysis session. Clin Nephrol 1985; 24: 1-4. (Pubitemid 15032650)
18. Speiser W, Wojta J, Korninger C, Kirchheimer C, Zazgornik J, Binder BR. Enhanced fibrinolysis caused by tissue plasminogen activator release in hemodialysis. Kidney Int 1987; 32: 280-283. (Pubitemid 17130800)
19. Shigeo T, Yoshihiro N, Fusae D, Ryoichi A, Yoshiko C, Fumiaki M. Coagulation and fibrinolysis in patients with chronic renal failure undergoing conservative treatment. Thromosis Research 1994; 64: 81-90.
20. Sagripanti A, Cupisti A, Baicchi U, Ferdeghini M, Morelli E, Barsotti G. Plasma parameters of the prothrombotic state in chronic uremia. Nephron 1993; 63: 273-278. (Pubitemid 23082067)
21. Nakamura Y, Chida Y, Tomura S. Enhanced coagulation-fibrinolysis in patients on regular hemodialysis treatment. Nephron 1991; 58: 201-204.
22. Sagripanti A, Cozza V, Baicchi U, Camici M, Cuspisti A, Barsotti G. Increased thrombin generation in patients with chronic renal failure. Int J Clin Lab Res 1997; 27: 72-75. (Pubitemid 27284726)
23. Tomura S, Nakamura Y, Deguchi F, Ando R, Chida Y, Marumo F. Coagulation and fibrinolysis in patients with chronic renal failure undergoing conservative treatment. Thromb Res 1991; 64: 81-90.
24. Ross R. The pathogenesis of atherosclerosis: An update. N Engl J Med 1986; 314: 488-499. (Pubitemid 16161950)
25. Al-Saady NM, Leatham EW, Gupta S, Kwan JT, Eastwood JB, Seymour CA. Monocyte expression of tissue factor and adhesion molecules: The link with accelerated coronary artery disease in patients with chronic renal failure. Heart 1999; 81: 134-140. (Pubitemid 29119386)
26. Bonomini M, Sirolli V, Merciaro G, Antidormi T, DiLiberato L, Brummer U, et al. Red blood cells may contribute to hypercoagulability in uraemia via enhanced surface exposure of phosphatidylserine. Nephrol Dial Transplant 2005; 20: 361-366. (Pubitemid 40276893)
27. Homma T, Ichikawa T. Studies of fibrinolytic activity of uraemic and long term hemodialytic patients with special reference to fibrinolytic inhibitor. Biochem Exp Biol 1979; 15: 229-236. (Pubitemid 10015275)
28. Nishimoto K, Yamagami S, Katoh Y, Kishimoto T, Maekawa M, Okada K, et al. Coagulation and fibrinolysis in chronic renal failure: Change in tissue-type plasminogen activator activity. Trans Am Soc Artif Intern Organs 1986; 2: 478-481.
29. Bergstein JM, Kuederli U, Bang NU. Plasma inhibitor of glomerular fibrinolysis inthe hemolytic-uremic syndrome. Am J Med 1982; 73: 322-327. (Pubitemid 12031780)
30. Brommer EJ, Schicht I, Wijngaards G, Verheijen JH, Rijken DC. Fibrinolytic activators and inhibitors in terminal renal insufficiency and in anephric patients. Thromb Haemost 1984; 52: 311-314. (Pubitemid 15156411)
31. Enta K, Iwade K, Aosaki M, Uchida T, Kasanuki H. Predictive value of coagulative molecular markers for thromboembolism in patients with nonvalvular atrial fibrillation: Prospective five year follow-up study. J Cardiol 2004; 44: 223-232. (Pubitemid 40762623)
32. Nozawa T, Inoue H, Hirai T, Iwasa A, Okumura K, Lee DJ, et al. D-dimer level influences thromboembolic events in patients with atrial fibrillation. Int J Cardiol 2006; 109: 59-65.
33. Nina V, Alenka M, Katarina K, Mojca S. High D-dimer levels predict cardiovascular events in patients with chronic atrial finrillation during oral anticoagulant therapy. Thromb Haemost 2003; 90: 1163-1172. (Pubitemid 38004439)